Annual SG&A
$34.31 M
+$19.28 M+128.18%
31 December 2023
Summary:
Zevra Therapeutics annual selling, general & administrative expenses is currently $34.31 million, with the most recent change of +$19.28 million (+128.18%) on 31 December 2023. During the last 3 years, it has risen by +$26.39 million (+333.20%). ZVRA annual SG&A is now at all-time high.ZVRA Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$16.21 M
+$3.60 M+28.59%
30 September 2024
Summary:
Zevra Therapeutics quarterly selling, general & administrative expenses is currently $16.21 million, with the most recent change of +$3.60 million (+28.59%) on 30 September 2024. Over the past year, it has increased by +$10.39 million (+178.58%). ZVRA quarterly SG&A is now at all-time high.ZVRA Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.72 B
-$130.08 M-8.17%
30 September 2024
Summary:
Zevra Therapeutics TTM selling, general & administrative expenses is currently -$1.72 billion, with the most recent change of -$130.08 million (-8.17%) on 30 September 2024. Over the past year, it has dropped by -$1.75 billion (-7149.22%). ZVRA TTM SG&A is now -3333.12% below its all-time high of $53.40 million, reached on 30 September 2024.ZVRA TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZVRA Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +128.2% | +178.6% | -7149.2% |
| 3 y3 years | +333.2% | +732.0% | -10000.0% |
| 5 y5 years | +174.3% | +348.6% | -10000.0% |
ZVRA Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +333.2% | at high | +732.0% | -63.4% | at low |
| 5 y | 5 years | at high | +333.2% | at high | +1077.9% | -83.8% | at low |
| alltime | all time | at high | +2439.9% | at high | +2935.2% | -3333.1% | at low |
Zevra Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $16.21 M(+28.6%) | $53.40 M(+24.2%) |
| June 2024 | - | $12.60 M(+26.9%) | $43.01 M(+16.2%) |
| Mar 2024 | - | $9.93 M(-32.2%) | $37.02 M(+7.9%) |
| Dec 2023 | $34.31 M(+128.2%) | $14.66 M(+151.9%) | $34.31 M(+40.5%) |
| Sept 2023 | - | $5.82 M(-12.0%) | $24.43 M(+8.2%) |
| June 2023 | - | $6.61 M(-8.5%) | $22.59 M(+15.6%) |
| Mar 2023 | - | $7.23 M(+51.4%) | $19.53 M(+29.9%) |
| Dec 2022 | $15.04 M(+72.8%) | $4.77 M(+20.1%) | $15.04 M(+17.3%) |
| Sept 2022 | - | $3.97 M(+11.7%) | $12.82 M(+18.8%) |
| June 2022 | - | $3.56 M(+30.1%) | $10.80 M(+13.1%) |
| Mar 2022 | - | $2.73 M(+7.0%) | $9.54 M(+9.7%) |
| Dec 2021 | $8.70 M(+9.8%) | - | - |
| Dec 2021 | - | $2.56 M(+31.2%) | $8.70 M(+0.3%) |
| Sept 2021 | - | $1.95 M(-15.5%) | $8.67 M(+6.4%) |
| June 2021 | - | $2.31 M(+21.8%) | $8.15 M(+7.7%) |
| Mar 2021 | - | $1.89 M(-25.2%) | $7.57 M(-4.5%) |
| Dec 2020 | $7.92 M(-26.8%) | $2.53 M(+76.9%) | $7.92 M(+17.0%) |
| Sept 2020 | - | $1.43 M(-16.9%) | $6.77 M(-24.4%) |
| June 2020 | - | $1.72 M(-23.4%) | $8.95 M(-12.4%) |
| Mar 2020 | - | $2.25 M(+63.2%) | $10.22 M(-5.5%) |
| Dec 2019 | $10.82 M | $1.38 M(-61.9%) | $10.82 M(-12.8%) |
| Sept 2019 | - | $3.61 M(+20.9%) | $12.40 M(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $2.99 M(+5.3%) | $11.78 M(-3.5%) |
| Mar 2019 | - | $2.84 M(-4.3%) | $12.21 M(-2.4%) |
| Dec 2018 | $12.51 M(-2.1%) | $2.96 M(-0.9%) | $12.51 M(+2.9%) |
| Sept 2018 | - | $2.99 M(-12.5%) | $12.16 M(-2.6%) |
| June 2018 | - | $3.42 M(+9.2%) | $12.48 M(-1.2%) |
| Mar 2018 | - | $3.13 M(+19.8%) | $12.64 M(-1.0%) |
| Dec 2017 | $12.77 M(-8.8%) | $2.61 M(-21.2%) | $12.77 M(-2.0%) |
| Sept 2017 | - | $3.32 M(-7.1%) | $13.03 M(+1.7%) |
| June 2017 | - | $3.57 M(+9.4%) | $12.82 M(-5.3%) |
| Mar 2017 | - | $3.27 M(+13.7%) | $13.53 M(-3.4%) |
| Dec 2016 | $14.00 M(+57.6%) | $2.87 M(-7.4%) | $14.00 M(+2.2%) |
| Sept 2016 | - | $3.10 M(-27.6%) | $13.69 M(+7.5%) |
| June 2016 | - | $4.29 M(+14.7%) | $12.74 M(+9.4%) |
| Mar 2016 | - | $3.74 M(+45.6%) | $11.64 M(+31.1%) |
| Dec 2015 | $8.88 M(+96.3%) | $2.57 M(+19.2%) | $8.88 M(+12.5%) |
| Sept 2015 | - | $2.15 M(-32.5%) | $7.89 M(+15.6%) |
| June 2015 | - | $3.19 M(+226.3%) | $6.83 M(+37.4%) |
| Mar 2015 | - | $977.00 K(-38.0%) | $4.97 M(+9.8%) |
| Dec 2014 | $4.53 M(+235.0%) | $1.58 M(+45.2%) | $4.53 M(+53.5%) |
| Sept 2014 | - | $1.09 M(-18.3%) | $2.95 M(+58.3%) |
| June 2014 | - | $1.33 M(+149.1%) | $1.86 M(+249.1%) |
| Mar 2014 | - | $534.00 K | $534.00 K |
| Dec 2013 | $1.35 M | - | - |
FAQ
- What is Zevra Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Zevra Therapeutics?
- What is Zevra Therapeutics annual SG&A year-on-year change?
- What is Zevra Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Zevra Therapeutics?
- What is Zevra Therapeutics quarterly SG&A year-on-year change?
- What is Zevra Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Zevra Therapeutics?
- What is Zevra Therapeutics TTM SG&A year-on-year change?
What is Zevra Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of ZVRA is $34.31 M
What is the all time high annual SG&A for Zevra Therapeutics?
Zevra Therapeutics all-time high annual selling, general & administrative expenses is $34.31 M
What is Zevra Therapeutics annual SG&A year-on-year change?
Over the past year, ZVRA annual selling, general & administrative expenses has changed by +$19.28 M (+128.18%)
What is Zevra Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of ZVRA is $16.21 M
What is the all time high quarterly SG&A for Zevra Therapeutics?
Zevra Therapeutics all-time high quarterly selling, general & administrative expenses is $16.21 M
What is Zevra Therapeutics quarterly SG&A year-on-year change?
Over the past year, ZVRA quarterly selling, general & administrative expenses has changed by +$10.39 M (+178.58%)
What is Zevra Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of ZVRA is -$1.72 B
What is the all time high TTM SG&A for Zevra Therapeutics?
Zevra Therapeutics all-time high TTM selling, general & administrative expenses is $53.40 M
What is Zevra Therapeutics TTM SG&A year-on-year change?
Over the past year, ZVRA TTM selling, general & administrative expenses has changed by -$1.75 B (-7149.22%)